http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104768551-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate | 2013-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104768551-B |
| titleOfInvention | Using Rebamipide as active ingredient and comprising hyperlipidemia and associated disease prevention or therapeutic composition |
| abstract | Preventing or treating the pharmaceutical use of the Rebamipide used in hyperlipidemia and associated disease the present invention relates to a kind of, more particularly to using Rebamipide as active ingredient and comprising hyperlipidemia and associated disease prevention or therapeutic composition.Rebamipide compound according to the present invention suppresses the generation as the TNF a of hyperlipidemia induction inflammatory cytokine, IL 6 and IL 1b secreted in macrophage；And suppress to form the generation of the foam cells (Foam cell) of arteriosclerosis plaque (Artherosclerotic plaque) precursor；Reducing T-CHOL, LDL cholesterol and neutral fat numerical value in blood improves blood lipid；Improve fatty liver；Suppress the activity of B cell；The expression of the Th17 of the generation of acceleration arteriosclerosis plaque is reduced, while the expression of the Treg cells for the reaction that can control inflammation can be increased.Accordingly, Rebamipide compound be advantageously used by various mechanism as described above for can prevent or treat hyperlipidemia and associated arteriosclerosis, heart failure, hypertensive cardiopathy pharmaceutical compositions.In addition, also without the toxicity as medicine and side effect, thus also can securely be used during long-term use, and to having stable effect in vivo. |
| priorityDate | 2012-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 341.